Third-line Targeted Therapy in Metastatic Renal Cell Carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium

• Published in: European urology Vol. 71; no. 2; pp. 204 - 209
• Main Authors: Wells, J. Connor, Stukalin, Igor, Norton, Craig, Srinivas, Sandy, Lee, Jae Lyun, Donskov, Frede, Bjarnason, Georg A, Yamamoto, Haru, Beuselinck, Benoit, Rini, Brian I, Knox, Jennifer J, Agarwal, Neeraj, Ernst, D. Scott, Pal, Sumanta K, Wood, Lori A, Bamias, Aristotelis, Alva, Ajjai S, Kanesvaran, Ravindran, Choueiri, Toni K, Heng, Daniel Y.C
• Format: Journal Article
• Language: English
• Published: Switzerland Elsevier B.V 01.02.2017
• Subjects: Antineoplastic Agents - therapeutic use; Carcinoma, Renal Cell - drug therapy; Carcinoma, Renal Cell - mortality; Carcinoma, Renal Cell - secondary; Databases, Factual; Female; Humans; Internationality; Kidney Neoplasms - drug therapy; Kidney Neoplasms - mortality; Kidney Neoplasms - secondary; Male; Metastatic renal cell carcinoma; Retrospective Studies; Risk Assessment; Survival Analysis; Targeted therapy; Third line therapy; Urology; Metastatic renal cell carcinoma; Targeted therapy; Third line therapy
• ISSN: 0302-2838; 1873-7560
• DOI: 10.1016/j.eururo.2016.05.049

Abstract Background The use of third-line targeted therapy (TTT) in metastatic renal cell carcinoma (mRCC) is not well characterized and varies due to the lack of robust data to guide treatment decisions. This study examined the use of third-line therapy in a large international population. Objective To evaluate the use and efficacy of targeted therapy in a third-line setting. Design, setting, and participants Twenty-five international cancer centers provided consecutive data on 4824 mRCC patients who were treated with an approved targeted therapy. One thousand and twelve patients (21%) received TTT and were included in the analysis. Outcome measurements and statistical analysis Patients were analyzed for overall survival (OS) and progression-free survival using Kaplan-Meier curves, and were evaluated for overall response. Cox regression analyses were used to determine the statistical association between OS and the six factors included in the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) prognostic model. Subgroup analysis was performed on patients stratified by their IMDC prognostic risk status. Results and limitations Everolimus was the most prevalent third-line therapy (27.5%), but sunitinib, sorafenib, pazopanib, temsirolimus, and axitinib were all utilized in over ≥9% of patients. Patients receiving any TTT had an OS of 12.4 mo, a progression-free survival of 3.9 mo, and 61.1% of patients experienced an overall response of stable disease or better. Patients not receiving TTT had an OS of 2.1 mo. Patients with favorable- (7.2%) or intermediate-risk (65.3%) disease had the highest OS with TTT, 29.9 mo and 15.5 mo, respectively, while poor-risk (27.5%) patients survived 5.5 mo. Results are limited by the retrospective nature of the study. Conclusions TTT remains highly heterogeneous. The IMDC prognostic criteria can be used to stratify third-line patients. TTT use in favorable- and intermediate-risk patients was associated with the greatest OS. Patient summary Patients with favorable- and intermediate-prognostic criteria disease treated with third-line targeted therapy have an associated longer overall survival compared with those with poor risk disease.